Skip to main content
SNY
NASDAQ Life Sciences

Sanofi Secures German Regulatory Clearance for Dynavax Acquisition

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$46.58
Mkt Cap
$111.753B
52W Low
$44.617
52W High
$60.115
52W Position info
4.4% above low
Off High info
23% below high
Rel. Volume info
2.3× avg
Market data snapshot near publication time

SNY is trading near its 52-week low of $44.617 (4.4% above the low) on elevated volume (2.3× avg).

Summary

Sanofi announced that it has received German foreign direct investment clearance, a key condition for its tender offer to acquire Dynavax Technologies Corporation.


Key Events · M&A and Partnerships · SNY

  • German FDI Clearance Obtained

    The Federal Ministry for Economic Affairs and Energy (BMWK) cleared the acquisition of Dynavax GmbH, a condition for the overall tender offer.

  • Acquisition Progresses

    This clearance, effective January 29, 2026, marks another significant step towards completing Sanofi's tender offer for Dynavax Technologies, following the HSR waiting period expiration.


Analysis · SNY · Life Sciences

This amendment signals significant progress towards the completion of Sanofi's acquisition of Dynavax Technologies. The clearance from the German Federal Ministry for Economic Affairs and Energy removes a critical regulatory condition, de-risking the transaction and moving it closer to its expected close. This follows the expiration of the HSR waiting period announced on January 28, 2026, indicating a steady progression through regulatory approvals since the initial tender offer on January 12, 2026.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SNY was trading at $46.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $111.8B. The 52-week trading range was $44.62 to $60.12. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SNY - Latest Insights

SNY
Nov 19, 2026, 8:59 AM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $46.16
Real-time Price: $46.52 info
Change: +$0.365 (+0.79%) info
Market Cap: $110.2B info
SNY
Oct 30, 2026, 3:54 AM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $43.03
Real-time Price: $46.52 info
Change: +$3.49 (+8%) info
Market Cap: $110.2B info
SNY
Oct 01, 2026, 5:22 AM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $41.31
Real-time Price: $46.52 info
Change: +$5.21 (+13%) info
Market Cap: $110.2B info
SNY
Sep 17, 2026, 6:09 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $42.71
Real-time Price: $46.52 info
Change: +$3.81 (+9%) info
Market Cap: $110.2B info
SNY
Aug 06, 2026, 6:02 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $43.26
Real-time Price: $46.52 info
Change: +$3.26 (+8%) info
Market Cap: $110.2B info